By Michael Nevradakis, Ph.D. | The Defender | February 3, 2023 Merck’s oral antiviral pill for COVID-19, molnupiravir — marketed under the name Lagevrio — may be fueling the development of new and potentially deadly variants of COVID-19, according to the authors of a new preprint study. The study, released Jan. 27 by a team of U.S. and U.K […]
By John Droz, Jr., M.S. | The Defender | March 7, 2022 The U.S. Food and Drug Administration (FDA) in December 2021 granted Emergency Use Authorization (EUA) to two COVID-19 early treatment oral drugs: Pfizer’s Paxlovid and Merck’s molnupiravir. This was a major milestone, as until then, there were no FDA-endorsed pharmaceutical pill options for people diagnosed with COVID-19. The standard […]
By Ryan Matters | OffGuardian | October 28, 2021 What happens when you fail in your attempts to create a vaccine for “Covid-19” and then realize you’ve just missed out on a billion-dollar profit-making opportunity? You hurriedly develop a new drug, rush it through a clinical trial (which you yourself design to ensure good results), and then announce it […]
By Andrew Bannister | Trial Site News | June 27, 2021 All dangerous diseases are best treated early. A major failure of the global COVID-19 strategy has been to wait a week for the disease to become dangerous, when breathing becomes a problem. Early treatment of COVID, even for those with mild symptoms, prevents later […]
